|Bid||3.8300 x 900|
|Ask||3.8400 x 2900|
|Day's Range||3.7300 - 3.8550|
|52 Week Range||2.3500 - 5.3700|
|Beta (3Y Monthly)||-0.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.21|
No resolution seems on the horizon on the U.S.-China trade front as both sides have dug in their heels. Since the end of February the S&P 500 has continued to advance despite a pullback in May, while the Russell 2000 has stalled out. Let's look at three small-caps that seem like good bargains at current trading levels, starting with BioDelivery Sciences International Inc. .
Regional Commercial Plans Improved Access for More Than 6 Million Lives During 2Q More Than 90% of Commercial Lives Now Have Access to BELBUCA in the U.S. RALEIGH, N.C., July.
Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.
The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...
BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically IndicatedHaving Payers Provide Coverage and.
The Zacks Analyst Blog Highlights: Middlesex Water, Atlantic Power, NexPoint Residential Trust, Illumina and BioDelivery Sciences International
The Fed has said that adoption of more accommodative policy is gaining ground as some economic developments raised concerns about U.S. and global growth.
RALEIGH, N.C., June 20, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is set to be added to the broad-market Russell 3000® Index as well as the Russell 2000®.
The market has been volatile in the last 6 months as the Federal Reserve continued its rate hikes and then abruptly reversed its stance and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF […]
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A renegotiated loan agreement will bring a Triangle public company $20 million more credit – but it also spells a remarkable transformation in the company's financial position.
RALEIGH, N.C., May 29, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
New Agreement is Cash Flow Accretive, Lowers Cost of Capital and Extends Debt Maturity Reduces Annual Interest Costs by Approximately $1.5 million Increases Flexibility to.
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
BioDelivery (BDSI) incurs narrower-than-expected loss in Q1. Sales surpass the consensus mark. The company raises guidance for 2019.